Scripps Research Institute Chemists Discover Structure of Cancer Drug Candidate

Chemists have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients. In the new study, scientists show that TIC10’s structure differs subtly from a version published by another group last year, and that the previous structure associated with TIC10 in fact describes a molecule that lacks TIC10’s anticancer activity.(10.1002/ange.201402133)


Author: Robert Slinn

Robert Slinn is ChemSpy's guest columnist. You can read his chemical news updates under the banner "Slinn Pickings". Robert is a Chartered Chemist (CChem), Member of the Royal Society of Chemistry (MRSC) and is a Visiting Researcher in the Department of Chemistry at the University of Liverpool. He has extensive experience in R&D: synthesis, analysis and analytical methods development; troubleshooting, consultancy, and teaching/training methods in industry and in academia. Robert is also 'Physical Methods' author for the Specialist Periodical Report series 'Organophosphorus Chemistry', published by Royal Society of Chemistry, Cambridge, UK. Robert has worked alongside David on the Bedside Book of Chemistry and a major Thomson-Reuters report on the state of the pharmaceutical industry for the 2011 International Year of Chemistry